Cannabidiol for the Treatment of Drug-Resistant Epilepsy in Children: Current State of Research
Cannabidiol for the Treatment of Drug-Resistant Epilepsy in Children: Current State of Research
复制标题
DOI：
10.1055/s-0037-1598109
复制
发表时间：
2017-08-01
影响因子：
0.2
通讯作者：
Carney, Paul R.
中科院分区：
文献类型：
--
作者：
Anderson, Christopher L.;Evans, Victoria F.;Carney, Paul R.
据报道，这些家庭制剂的有效性，特别是那些大麻二酚 (CBD) 浓度高的制剂，引起了医学界的关注。特别是大麻，以其缺乏精神活性作用和高 CBD 含量而闻名，已成为医学研究的目标。公众和政治兴趣转向 CBD 的医学应用，需要对其功效进行重新研究。尤其是儿科人群，如果更好地了解这种新疗法的安全性和有效性，将会受益匪浅。这篇综述讨论了 CBD 研究的现状，并确定了与儿童癫痫人群相关的需要进一步研究的领域。它将特别涵盖那些患有难治性癫痫且其他治疗方法不足以治疗的患者。
The reported effectiveness of these home preparations, especially those with high cannabidiol (CBD) concentrations, has garnered the attention of the medical community. In particular cannabis sativa, known for its lack of a psychoactive effect and high CBD content, has become a target of medical research. The shift in public and political interest to medicinal applications of CBD demands renewed research into its efficacy. Pediatric populations in particular stand to benefit significantly from a better understanding of the safety and efficacy of this novel treatment. This review discusses the current state of CBD research and identifies areas that require further investigation as they pertain to pediatric epilepsy populations. It will especially cover those suffering from refractory epilepsies for which other methods of remediation have not sufficed.